Medigene has received further results from the clinical phase I / II study with the company’s dendritic cell vaccine in patients with acute myeloid leukemia. “A more detailed analysis of the results from the study has shown that the increased presence of T-cell activation markers in the bone marrow seems to be associated with a decrease in the disease (remission). In contrast, an increased mutation of various genes in the leukemia cells was associated with the onset of the disease again, ”said Medigene on Monday. The previously presented topline results of the study with the cell vaccine showed excellent data on safety and feasibility, according to the biotech company.
“The treatment of AML patients with autologous DC vaccines in this study produced encouraging results over the two-year course of the study. We continue to monitor the patients and are still delighted with the overall result, ”says Yngvar Floisand, chief physician of the department of hematology at Oslo University Hospital and lead investigator of the study. Floisand presented the results over the weekend at the 62nd annual virtual meeting of the American Society of Hematology.